Surveillance of Complex Renal Cysts - the SOCRATIC Pilot Study

Renal Cyst Clinical Trial

— SOCRATICp  

Official title:

Surveillance of Complex Renal Cysts - the SOCRATIC Pilot Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04079764
• Other study ID #: 2020-2871
• Status: Completed
• Start date: September 30, 2019
• Est. completion date: December 31, 2022

Study information

• Verified date: February 2024
• Source: Centre de recherche du Centre hospitalier universitaire de Sherbrooke
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

One third of individuals aged >60 years will be diagnosed with at least one renal cyst following abdominal imaging. These cystic lesions are categorized according to the Bosniak classification which categorizes cysts according to their degree of complexity and risk of malignancy. Growing evidence suggests that a significant proportion of Bosniak III and IV cysts are benign and that the malignant ones present low metastatic potential. Since renal surgery carries substantial morbidity (20%) and potential mortality (0.5%), active surveillance has gained attention as a potential tradeoff to surgery to overcome overtreatment. Therefore, prospective studies of long-term follow-up are needed to confirm the oncologic outcomes of this strategy for Bosniak III/IV cysts. We first designed a pilot study that will assess the feasibility of a subsequent larger multicenter observational study aiming to ascertain mid-term safety of active surveillance. The objectives of this pilot study are a) Determining patients and urologists buy-in and barriers to the proposed intervention; b) Collecting perceptions and concerns of patients and urologists; c)

Description:

STUDY DESIGN - This is a two-arm multicenter prospective observational pilot study where patients with Bosniak III or IV choosing either active surveillance or surgery will be monitored closely. OBJECTIVES - PRIMARY Validate the feasibility issues (acceptability, recruitment rate, costs, protocol adherence and implementation of imaging central review) of an observational study on the treatments of complex cysts. SECONDARY a- Validate the inclusion and exclusion criteria in regard to the feasibility of the study; b- Validate the triggers for discontinuation of AS in terms of feasibility and safety for the patients. POPULATION - For the pilot study, the intended targeted population will be patients incidentally diagnosed with a Bosniak III or IV cysts and who opted to be managed by either surgery or active surveillance. METHODOLOGY - Upon written consent, patients will be explained the followup scheme which will consist of a semi-annual visits for 1 year. To mimic the upcoming larger study and to evaluate visit feasibility issues, the baseline and the follow-up visits will consist of the following items: blood results, CT-scan result, quality of life questionnaires and medical data. Baseline (prior to study entry) and follow-up abdominal imaging (CT/MRI) suspicious for progression will be reviewed centrally by an interventional radiologist at the CIUSSSE-CHUS, to confirm Bosniak classification.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: December 31, 2022
• Est. primary completion date: August 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. aged =18 years at the time of diagnosis

2. diagnosed with a Bosniak III or IV cyst

3. size of cystic component =7cm

4. solid component =2 cm in maximal diameter for Bosniak IV cysts

5. life expectancy >5 years (by physician's estimate)

6. diagnosis =6 months from accrual date

7. currently asymptomatic from the disease

8. deemed fit enough for surgery

9. willingness and ability to complete questionnaires in either French or English

10. able and willing to provide informed consent.

Exclusion Criteria:

1. history of a hereditary renal cancer syndrome

2. presence of polycystic kidney disease

3. systemic therapy for another malignancy within 12 months of recruitment date

4. uncontrolled medical illness including infections, hypertension, arrhythmias, heart failure, or myocardial infarction/unstable angina within 6 months that would predispose to immediate surgical therapy

5. metastatic disease or evidence of vascular or nodal disease

6. unwillingness to undergo monitoring and imaging studies

7. any contra-indication(s) to contrast-enhanced imaging (estimated glomerular filtration rate <30min/mL)

Related Conditions & MeSH terms

• Cysts
• Renal Cyst

Locations

Country	Name	City	State
Canada	St Joseph's Healthcare	Hamilton	Ontario
Canada	Centre de recherche du Centre hospitalier Universitaire de Sherbrooke	Sherbrooke	Quebec
Canada	Princess Margaret Cancer Center	Toronto	Ontario

Sponsors (3)

Lead Sponsor	Collaborator
Centre de recherche du Centre hospitalier universitaire de Sherbrooke	Canadian Urological Association, Kidney Cancer Canada

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Acceptability	defined by the number of patients that accept to be enrolled over the number of patients that were screened eligible	at baseline (at enrollment, no longer than 6 months after diagnosis)
Primary	recruitment rate	defined by the number of patients that actually were enrolled per month per participating site	at baseline (at enrollment, no longer than 6 months after diagnosis)
Primary	study costs	defined by costs for research resources involved per patient per participating site	at the end of study (1 year after enrollment/signature of consent)
Primary	study compliance	defined by the percentage of total deviations (missing data, missing visits or visits out of timeframe)	at the end of study (1 year after enrollment/signature of consent)